newsfilter
← Latest News
Business Wire·

Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine

FAP-2286 is an investigational targeted radionuclide therapeutic and imaging agent targeting fibroblast activation protein (FAP) Clovis Oncology initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in pati